Anti-Inflammatory and Gastroprotective Evaluation of Prodrugs of Piroxicam

Table 1

Pharmacological screening of piroxicam and ester prodrugs 3(a–e).

Compound	Anti-inflammatory activity (% inhibition)						Ulcer index*
	1 h	2 h	3 h	4 h	5 h	6 h
Piroxicam	12.76 ± 0.96	24.60 ± 1.50	37.87 ± 2.0*	44.97 ± 3.0	50.46 ± 2.80	56.53 ± 3.0*	2.67 ± 0.51
3a	16.65 ± 3.1	28.80 ± 1.4	43.93 ± 2.7*	55.77 ± 4.9	55.44 ± 1.6	60.44 ± 4.1*	1.08 ± 0.73
3b	19.42 ± 1.1	33.62 ± 2.6	48.58 ± 3.3*	65.11 ± 3.7	61.82 ± 1.2	65.79 ± 4.2*	1.16 ± 0.60
3c	27.33 ± 1.4	43.07 ± 1.3	55.68 ± 1.7*	72.32 ± 1.6	71.78 ± 2.2	75.10 ± 2.4*	0.83 ± 0.25
3d	23.22 ± 1.6	38.52 ± 3.3	52.51 ± 1.5*	72.58 ± 4.6	66.55 ± 2.3	71.14 ± 4.1*	0.91 ± 0.20
3e	27.38 ± 3.8	38.76 ± 3.4	57.33 ± 2.6*	70.20 ± 0.8	75.74 ± 1.3	76.06 ± 0.6*	0.67 ± 0.25

Data represented as mean ± SEM, .
*Statistical analysis was performed with ANOVA followed by Dunnett test with respect to control.